Dateline City:
SAN ANTONIO
18.5 Percent Overall Response Rate Observed in KEYTRUDA-Treated Patients with This Aggressive Form of Breast Cancer
Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-086)
SAN ANTONIO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today early study findings demonstrating an overall response
rate of 18.5 percent with KEYTRUDA, the companys anti-PD-1 therapy, as
assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive,
advanced triple-negative breast cancer one of the most aggressive
forms of breast cancer.
Language:
English
Contact:
MerckMedia:Pamela Eisele, (267) 305-3558Claire Mulhearn, (908) 236-1118orInvestor:Joseph Romanelli, (908) 740-1986Justin Holko, (908) 740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more